Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

Summary

To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.

Detailed Description

Primary Objective: To establish MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project. * To prospectively identify, collect, and store all isolates causing proven or probable MCM in adult high-risk cancer participants. * To prospectively identify, collect, and store relevant host samples from high-risk participants developing proven or probable MCM, along with relevant biospecimens from three control groups. * To comprehensively annotate clinical specimens and provide information regarding the course and outcome of all MCM cases and controls. OUTLINE: This is an observational study. Patients are assigned to 1 of 4 groups. GROUP M: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP A: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP B: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP C: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.

Eligibility Criteria

Interventions